. "Appendix A: Biographic information on the Committee on Toxicity Testing and Assessment of Environmental Agents ." Toxicity Testing for Assessment of Environmental Agents: Interim Report. Washington, DC: The National Academies Press, 2006.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Toxicity Testing for Assessment of Environmental Agents: Interim Report
systems of liver, heart, kidney, nerve, skin, and eye cells as experimental models to study the cellular and subcellular toxicity of selected xenobiotics. He was elected president of the Society of Toxicology, 2000-2001, and is editor of Toxicology In Vitro and the Target Organ Series on Cardiovascular Toxicology. Dr. Acosta serves as chair of the Food and Drug Administration (FDA) Scientific Advisory Board for the National Center for Toxicology Research and was a member of the Board of Scientific Councilors for the Office of Research and Development for the Environmental Protection Agency (EPA) for 2001-2004. He was a member of the Scientific Advisory Committee to the director of the National Center for Environmental Health of the Centers for Disease Control (CDC) for 2001-2003. He is serving on the Scientific Advisory Committee for Alternative Toxicological Methods for the National Institute for Environmental Health Sciences (NIEHS), and the Expert Committee on Toxicology and Biocompatibility for the US Pharmacopoeia (2000-2005). He also served on the NRC Howard Hughes Medical Institute Predoctoral Fellowships Panel on Neurosciences and Physiology. Dr. Acosta received his PhD in pharmacology and toxicology from the University of Kansas.
Melvin Andersen is director of the Computational Biology Division at the CIIT Centers for Health Research. Previously, he held positions in toxicology research and research management in the federal government (Department of Defense and EPA) and was professor of environmental health at Colorado State University. He has worked to develop biologically realistic models of the uptake, distribution, metabolism, and biologic effects of drugs and toxic chemicals and has applied these physiologically based pharmacokinetic and pharmacodynamic models to safety assessments and quantitative health risk assessments. His current research interests include developing mathematical descriptions of control of genetic circuitry in the developing and adult organism and the dose-response and risk-assessment implications of the control processes. Dr. Andersen is board-certified in industrial hygiene and in toxicology. He has served on numerous NRC committees, including the Committee on Toxicology, the Committee on Toxicological Effects of Mercury, the Committee on Risk Assessment Methodology, and the Subcommittee on Pharmacokinetics. He earned a PhD in biochemistry and molecular biology from Cornell University.